2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 604

Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Abstract Number: 991

CaMK4 Facilitates Recruitment of IL-17 Producing Cells to Target Organs through the CCR6/CCL20 Axis in Th17-Driven Inflammatory Diseases
Abstract Number: 550

Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?
Abstract Number: 1299

Can Bone Marrow Lesions be Scored More Reliably and Responsively in Knee Osteoarthritis Using a Web-Based Overlay System (KIMRISS) Than By Standard MRI Osteoarthritis Knee Scoring (MOAKS)? Data from the Osteoarthritis Initiative and a Prospective Trial of Adaluminab Therapy
Abstract Number: 630

Can Extraglandular Manifestations Differentiate Primary Sjögren’s Syndrome from Sjögren’s-Systemic Lupus Erythematosus Overlap Syndrome?
Abstract Number: 2906

Can Immunosuppressive Drug Treatment Reduce Mortality in Patients with Systemic Lupus Erythematosus (SLE): A Propensity Score Analysis of a Longitudinal Cohort of 803 Patients?
Abstract Number: 1490

Can Patients Forget Their Artificial Joint after Arthroplasty?
Abstract Number: 1719

Can Structural Progression on MRI of Sacroiliac Joints in Patients with Spondyloarthritis be Reliably Detected and What Type of Calibration Is Necessary to Achieve This?
Abstract Number: 2234

Can the Fracture Risk Assessment Tool (FRAX) Also Predict Falls in Older Women?
Abstract Number: 662

Can the New Contest Questionnaire Identify Psoriatic Arthritis in a Primary Care Population?
Abstract Number: 3057

Can We Differentiate Takayasu’s Arteritis from Atherosclerosis Using Carotid Artery Doppler Usg?
Abstract Number: 2347

Can We Predict the Dose of Allopurinol to Achieve Target Urate?
Abstract Number: 1969

Can We Predict the Relapse of Giant Cell Arteritis?
Abstract Number: 365

Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials
Abstract Number: 2345

Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].